Cart
sales@molnova.com
VLX1570
CAS No. 1431280-51-1
VLX1570 ( VLX 1570;VLX-1570 )
Catalog No. M11824 CAS No. 1431280-51-1
VLX1570 is a small molecule b-AP15 analog that fucttion as proteasome deubiquitinase inhibitor with IC50 of 10 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 141 | In Stock |
|
| 5MG | 245 | In Stock |
|
| 10MG | 385 | In Stock |
|
| 25MG | 644 | In Stock |
|
| 50MG | 888 | In Stock |
|
| 100MG | 1233 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVLX1570
-
NoteResearch use only, not for human use.
-
Brief DescriptionVLX1570 is a small molecule b-AP15 analog that fucttion as proteasome deubiquitinase inhibitor with IC50 of 10 uM.
-
DescriptionVLX1570 is a small molecule b-AP15 analog that fucttion as proteasome deubiquitinase inhibitor with IC50 of 10 uM, interacts at the active sites of the proteasome DUBs USP14 and UCHL5; demonstrates cytotoxicity in survival assays in HCT116 colon cancer cells with IC50 of 0.58 uM, shows no inhibitory activity on a panel of recombinant non-proteasome DUBs, recombinant kinases, or caspase-3; decreases cell viability in chemotherapy resistant endometrial cancer cells consistent with cell cycle arrest and caspase-3 mediated apoptosis; decreases tumor burden and prolongs survival in WM-xenografted mice.Blood Cancer Phase 2 Clinical
-
SynonymsVLX 1570;VLX-1570
-
PathwayProteasome/Ubiquitin
-
TargetDUB
-
RecptorDUB
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1431280-51-1
-
Formula Weight469.39
-
Molecular FormulaC23H17F2N3O6
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=C1/C(CN(C(C=C)=O)CC/C1=C/C2=CC=C(F)C([N+]([O-])=O)=C2)=C\C3=CC=C(F)C([N+]([O-])=O)=C3
-
Chemical Name4H-Azepin-4-one, 3,5-bis[(4-fluoro-3-nitrophenyl)methylene]hexahydro-1-(1-oxo-2-propen-1-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wang X, et al. Chem Biol Drug Des. 2015 Nov;86(5):1036-48.
2. Vogel RI, et al. Oncotarget. 2016 May 24;7(21):30962-76.
3. Shukla N, et al. Cancer Res. 2016 Aug 1;76(15):4525-34.
4. Wang X, et al. Sci Rep. 2016 Jun 6;6:26979. doi: 10.1038/srep26979.
2. Vogel RI, et al. Oncotarget. 2016 May 24;7(21):30962-76.
3. Shukla N, et al. Cancer Res. 2016 Aug 1;76(15):4525-34.
4. Wang X, et al. Sci Rep. 2016 Jun 6;6:26979. doi: 10.1038/srep26979.
molnova catalog
